Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

被引:1
|
作者
Beauverd, Yan [1 ]
McLornan, Donal P. [1 ,2 ]
Radia, Deepti H. [1 ]
Harrison, Claire N. [1 ]
机构
[1] Guys & St Thomas NHS Fdn Trust, Dept Hematol, London, England
[2] Kings Coll Hosp NHS Fdn Trust, Dept Hematol Med, London, England
关键词
myeloproliferative neoplasms; outcomes; polycythemia vera; ruxolitinib; treatment; ESSENTIAL THROMBOCYTHEMIA; JAK INHIBITION; PRIMARY MYELOFIBROSIS; CELL-FUNCTION; LOW TOXICITY; HYDROXYUREA; SAFETY; HYDROXYCARBAMIDE; PHARMACOKINETICS; INTOLERANCE;
D O I
10.2217/fon-2015-0023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Current treatments for polycythemia vera have remained unchanged for decades with phlebotomy, hydroxycarbamide (also named hydroxyurea) and to a lesser extent interferon being the cornerstones in our therapeutic armamentarium. However, some patients do not respond to, or indeed experience significant side effects to, these current agents and development of alternative therapeutic options is required. Ruxolitinib, a potent JAK1/2 inhibitor, initially approved for myelofibrosis, was recently approved for patients with polycythemia vera refractory or intolerant to hydroxycarbamide. In this article, we review the currently available efficacy and safety data.
引用
收藏
页码:739 / 749
页数:11
相关论文
共 50 条
  • [21] RUXOLITINIB TREATMENT FOLLOWING INTERFERON IN PATIENTS WITH POLYCYTHEMIA VERA: AN ANALYSIS FROM THE RESPONSE TRIAL
    Kiladjian, J. J.
    Guglielmelli, P.
    Griesshammer, M.
    Masszi, T.
    Durrant, S.
    Passamonti, F.
    Jones, M. M.
    Zhen, H.
    Li, J.
    Gadbaw, B.
    Habr, D.
    Verstovsek, S.
    HAEMATOLOGICA, 2016, 101 : 563 - 564
  • [22] Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib
    Zeitler, Kristen
    Jariwala, Ripal
    Alrabaa, Sally
    Sriaroon, Chakrapol
    BMJ CASE REPORTS, 2021, 14 (11)
  • [23] Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
    Rohit Sekhri
    Parvis Sadjadian
    Tatjana Becker
    Vera Kolatzki
    Karlo Huenerbein
    Raphael Meixner
    Hannah Marchi
    Rudolf Wallmann
    Christiane Fuchs
    Martin Griesshammer
    Kai Wille
    Annals of Hematology, 2021, 100 : 2707 - 2716
  • [24] Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
    Sekhri, Rohit
    Sadjadian, Parvis
    Becker, Tatjana
    Kolatzki, Vera
    Huenerbein, Karlo
    Meixner, Raphael
    Marchi, Hannah
    Wallmann, Rudolf
    Fuchs, Christiane
    Griesshammer, Martin
    Wille, Kai
    ANNALS OF HEMATOLOGY, 2021, 100 (11) : 2707 - 2716
  • [25] Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera
    Sorensen, Anders Lindholm Lindholm
    Skov, Vibe
    Kjaer, Lasse
    Eickhardt-Dalboge, Christina Schjellerup Schjellerup
    Larsen, Morten Kranker
    Nielsen, Claus
    Thomsen, Carsten
    Gjerdrum, Lise Mette Rahbek
    Knudsen, Trine Alma
    Ellervik, Christina
    Overgaard, Ulrik Malthe
    Andersen, Christen Lykkegaard
    Bjorn, Mads Emil
    Hasselbalch, Hans Carl
    BLOOD, 2022, 140 : 6806 - 6807
  • [26] Ruxolitinib for the Treatment of Polycythemia Vera: Response on Alternative Dose Versus Standard Dose
    Cacciola, Emma
    Vecchio, Veronica
    Cacciola, Elio Gentilini
    Cacciola, Rossella Rosaria
    BLOOD, 2020, 136
  • [27] Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera
    Swei, Eric C.
    Fox, Charlie M.
    Bowles, Daniel W.
    Rizeq, Mona N.
    Onyiah, Joseph C.
    ACG CASE REPORTS JOURNAL, 2022, 9 (01)
  • [28] TREATMENT WITH ANAGRELIDE IN PATIENTS WITH POLYCYTHEMIA VERA
    Francisca, Ramis
    Alicia, Senin
    Ma Teresa, Gomez Casares
    Juan Carlos, Hernandez Boluda
    Encinas Manuel, Perez
    Ma Jose, Ramirez
    Ana, Kerguelen
    Joaquin, Martinez
    Jose M, Raya
    Carlos, Besses
    Alberto, Alvarez-Larran
    HAEMATOLOGICA, 2016, 101 : 189 - 189
  • [29] Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study
    Theocharides, Alexandre
    Gisslinger, Heinz
    De Stefano, Valerio
    Accurso, Vincenzo
    Iurlo, Alessandra
    Devos, Timothy
    Egyed, Miklos
    Lippert, Eric
    Delgado, Regina Garcia
    Cantoni, Nathan
    Dahm, Anders E. A.
    Sotiropoulos, Damianos
    Houtsma, Erik
    Smyth, Aoife
    Iqbal, Amir
    Di Matteo, Paola
    Zuurman, Mike
    te Boekhorst, Peter A. W.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (03) : 379 - 391
  • [30] Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial
    Verstovsek, Srdan
    Kiladjian, Jean-Jacques
    Mesa, Ruben
    Jones, Mark M.
    He, Shui
    Li, Jingjin
    Habr, Dany
    Vannucchi, Alessandro M.
    BLOOD, 2014, 124 (21)